Trials / Completed
CompletedNCT03092934
A Study of AK-01 (LY3295668) in Solid Tumors
A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or one other solid tumor type.
Conditions
- Neoplasms
- Neoplasm Metastasis
- Triple Negative Breast Neoplasms
- Head and Neck Neoplasms
- Breast Neoplasms
- Solid Tumor, Adult
- Small Cell Lung Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3295668 | Oral capsules |
Timeline
- Start date
- 2017-05-29
- Primary completion
- 2020-04-20
- Completion
- 2020-04-20
- First posted
- 2017-03-28
- Last updated
- 2021-07-02
- Results posted
- 2021-07-02
Locations
3 sites across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03092934. Inclusion in this directory is not an endorsement.